Department of Pharmacology, Penn State College of Medicine, Hershey, PA, United States.
Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Hershey, PA, United States.
Front Immunol. 2022 Dec 14;13:1029069. doi: 10.3389/fimmu.2022.1029069. eCollection 2022.
Immunotherapy has emerged as a breakthrough strategy in cancer treatment. mRNA vaccines are an attractive and powerful immunotherapeutic platform against cancer because of their high potency, specificity, versatility, rapid and large-scale development capability, low-cost manufacturing potential, and safety. Recent technological advances in mRNA vaccine design and delivery have accelerated mRNA cancer vaccines' development and clinical application. In this review, we present various cancer vaccine platforms with a focus on nucleic acid vaccines. We discuss rational design and optimization strategies for mRNA cancer vaccine development. We highlight the platforms available for delivery of the mRNA vaccines with a focus on lipid nanoparticles (LNPs) based delivery systems. Finally, we discuss the limitations of mRNA cancer vaccines and future challenges.
免疫疗法已成为癌症治疗的突破策略。mRNA 疫苗因其高效力、特异性、多功能性、快速和大规模开发能力、低成本制造潜力和安全性,成为一种有吸引力和强大的免疫治疗平台对抗癌症。mRNA 疫苗设计和传递方面的最新技术进步加速了 mRNA 癌症疫苗的开发和临床应用。在这篇综述中,我们展示了各种癌症疫苗平台,重点是核酸疫苗。我们讨论了 mRNA 癌症疫苗开发的合理设计和优化策略。我们强调了用于传递 mRNA 疫苗的平台,重点是基于脂质纳米粒(LNP)的传递系统。最后,我们讨论了 mRNA 癌症疫苗的局限性和未来的挑战。